Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia

Abstract

Continued research into the biology of acute lymphoblastic leukemia (ALL) and more precise methods of measuring residual disease allow for improved risk stratification and identification of the subset of patients who may benefit from hematopoietic cell transplantation (HCT) in first complete remission. Advances in HCT preparative regimens, donor selection, and graft-versus-host disease prophylaxis and treatment have resulted in fewer transplant-related morbidities and mortality and better survival outcomes. The development of effective immunotherapies, such as chimeric antigen receptor T-cell therapies, have significantly changed the treatment landscape of ALL, allowing patients with advanced disease to be considered for HCT with curative intent.